CASP8 and bladder transitional cell carcinoma: Our study also demonstrated that the expression level of CASP8 in BLCA was related to the drug sensitivity of various targeted therapies including FR-180204 (an ERK inhibitor), LY317615 (a PKCβ inhibitor), JNK VIII inhibitor, gefitinib (EGFR inhibitor), SNX-2112 (HSP inhibitor), and lapatinib (an EGFR/HER2 tyrosine kinase inhibitor).